Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice.
about
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.Mutant HRAS as novel target for MEK and mTOR inhibitorsTherapeutic potential of targeting acinar cell reprogramming in pancreatic cancerVEGF is an important mediator of tumor angiogenesis in malignant lesions in a genetically engineered mouse model of lung adenocarcinoma.MEK inhibitor PD-0325901 overcomes resistance to CK2 inhibitor CX-4945 and exhibits anti-tumor activity in head and neck cancer.MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.Contrast agents for quantitative microCT of lung tumors in mice.Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer.Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance.Induction of immunoglobulin transcription factor 2 and resistance to MEK inhibitor in melanoma cells.Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma.A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer.KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target.Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.
P2860
Q27852093-AC0AF1BB-1163-42B9-BC19-BE26FEB10EC9Q27853238-CFB8C80B-5F6E-41C0-9E48-4FC18409FDC8Q28068998-1C42B1F0-D2E4-40BC-89E8-309B1F5B3991Q34693856-C48A8B00-1BFC-4122-BB51-DB1A08C05ED7Q35197507-8E9F31FB-189C-40DB-B52C-A748A4C076E5Q36021572-6769C7E0-FF19-46EB-8458-8EAD63150F59Q37401047-A30362FB-C8EC-4676-8803-23A4E09AEE8BQ38199737-3ABFA8BA-B0A6-4320-8856-0CDD6C05AB37Q38385463-9D5E8C05-727C-49D6-B495-20995CCB16B4Q38402255-1D8052CB-1B4D-4186-A31A-AC918B87431CQ39105272-0E418BF1-7968-441A-B035-D06798EC87A9Q47130538-BF5F9A6D-D7D8-4755-980E-8BD4D6C71598Q49887897-EA8F3505-0B14-48D2-B9B2-926C721C9981Q51329014-6F91BA98-A94C-48A8-8BCE-D8F5738D5DD0
P2860
Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Combination of a MEK inhibitor ...... adenocarcinoma tumors in Kras
@nl
Combination of a MEK inhibitor ...... tumors in Kras(G12D-LSL) mice.
@en
type
label
Combination of a MEK inhibitor ...... adenocarcinoma tumors in Kras
@nl
Combination of a MEK inhibitor ...... tumors in Kras(G12D-LSL) mice.
@en
prefLabel
Combination of a MEK inhibitor ...... adenocarcinoma tumors in Kras
@nl
Combination of a MEK inhibitor ...... tumors in Kras(G12D-LSL) mice.
@en
P2093
P2860
P1476
Combination of a MEK inhibitor ...... tumors in Kras(G12D-LSL) mice.
@en
P2093
Anand Giddabasappa
Anthony Wong
Brett H Simmons
Brittany A Snider
Farbod Shojaei
James G Christensen
Jeetendra Eswaraka
Joseph H Lee
Julie L Kan
Kush Lalwani
P2860
P2888
P304
P356
10.1007/S00280-012-1899-6
P577
2012-06-09T00:00:00Z